GSK (LON:GSK) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Shares of GSK plc (LON:GSK) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,961.64 and traded as high as GBX 1,989.50. GSK shares last traded at GBX 1,958, with a volume of 6,270,777 shares.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research note on Thursday, May 28th. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research note on Thursday, March 26th. Shore Capital Group reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Citigroup dropped their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,900 price target on shares of GSK in a research note on Monday, June 8th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of GBX 2,034.29.

GSK Price Performance

The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74. The business has a fifty day simple moving average of GBX 1,967.58 and a 200 day simple moving average of GBX 1,963.79. The stock has a market capitalization of £79.07 billion, a P/E ratio of 13.88, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last issued its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. The firm had revenue of GBX 762.90 billion during the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. On average, analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Jonathan Symonds acquired 5,000 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was purchased at an average cost of GBX 1,951 per share, with a total value of £97,550. Also, insider Anne Beal acquired 196 shares of the firm’s stock in a transaction on Friday, March 20th. The shares were bought at an average cost of GBX 5,179 per share, with a total value of £10,150.84. In the last ninety days, insiders purchased 9,619 shares of company stock valued at $19,452,794. Corporate insiders own 0.31% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.